Our vision: to address the large unmet need for anti-inflammatory therapeutics for cardiovascular disease
Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of cardiovascular disease. The company started development of its lead program in 2008, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Sweden.
The company currently has a proprietary clinical development stage program with the lead candidate, ATH3G10.
Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB. The development of the antibody therapy has in part been co-financed by the EU FP7 program, in the project CARDIMMUN.
Athera is located in Stockholm at Hagastaden, next the new Karolinska Hospital and at AZ BioVentureHub, the incubator established at the Astra Zeneca facility in Gothenburg as an innovative ecosystem to further strengthen the life science industry in Scandinavia.
A dynamic company committed to
improving care for cardiovascular disease patients
Athera Biotechnologies AB is managed in a semi-virtual organization built by a core team of senior professionals with many years of experience from the pharmaceutical, biotechnology and diagnostics industries. Our expertise extends from preclinical and clinical development
to specialized knowledge in the development of cardiovascular pharmaceuticals, and intellectual property.
Management team members include
Carina Schmidt – Chief Executive Officer
Knut Pettersson – Chief Scientific Officer
Margareta Emås – CMC Project Manager
Anders Bergman – Chief Operations Officer
Board of Directors
|Svein Mathisen – MSc||Former CEO of Bioinvent International (publ)|
|Otto Skolling – MSc||The Foundation for Baltic and East European Studies (Östersjöstiftelsen)|
|Johan Kördel – PhD||Advisor to Industrifonden, venture investment and board professional. Senior Partner at Lundbeckfond Ventures in Denmark|
|Gunnar Olsson – MD, PhD||Chairman of the Board, former head of CV/GI in AstraZeneca|